GD2-specific chimeric antigen receptor-modified T-cell therapy against advanced neuroblastoma

我们使用piggyBac转座子和核感染系统成功地生成了嵌合抗原受体修饰的T细胞，并使用无血清培养系统有效地扩增了CAR-T细胞。gd2特异性CAR-T细胞在不同程度上诱导gd2阳性肿瘤细胞系（神经母细胞瘤、视网膜母细胞瘤、髓母细胞瘤和胶质母细胞瘤）的体外细胞死亡。此外，A剂的加入显著提高了抗肿瘤能力。考虑到非病毒基因修饰的简单性、安全性和成本效益，基于piggyBac转座子的gd2特异性t细胞疗法可能是治疗儿童神经源性肿瘤的一种新的治疗选择。

We successfully generated chimeric antigen receptor (CAR)-modified T cells using piggyBac transposon and nucleofection systems, and efficiently expanded the CAR-T cells using a serum-free culture system.GD2-specific CAR-T cells induced in vitro cell death to various extents against GD2-positive tumor cell lines (neuroblastoma, retinoblastoma, medulloblastoma, and glioblastom). Additionally, addition of the agent A markedly increased the anti-tumor ability.Considering the simplicity, safety, and cost-benefit of non-viral gene modification, piggyBac transposon-based GD2-specific T-cell therapy may be a novel therapeutic option against pediatric neurogenic tumors.